Context: After brain stem death (BSD), a low T 3 state is common, and T 3 supplementation has been advocated to improve heart function and yield for transplantation.
I
n critical illness, reduced peripheral conversion of T 4 leads to falling T 3 levels, whereas TSH and T 4 levels remain normal (1) (2) (3) . Reduced free T 3 (fT3) levels are predictive of mortality and are an important prognostic indicator in heart failure (4, 5) . However, T 3 supplementation in critically ill patients is of debated efficacy and, although able to increase serum T 3 , has failed to reduce mortality after cardiac surgery (6, 7), whereas T 4 therapy suppresses TSH without normalizing serum T 3 and fails to improve outcomes (8) . After brain stem death (BSD), a low T 3 state is common and may be exacerbated by hypothalamic-pituitary-thyroid axis failure (2, 9 -12) . Acute T 3 therapy post-BSD has a number of putative beneficial cardiovascular effects but remains a subject of debate (13) . In observational studies, thyroid hormone (TH) replacement has been associated with improved cardiac donor hemodynamic performance, reduction in inotrope requirements, and increased organ utilization (14, 15) , but randomized studies have not demonstrated hemodynamic benefit (16, 17) .
A number of rapid responses to T 3 therapy might be expected post-BSD, including systemic vasodilatation and positive inotropy. In experimental models, T 3 is associated with up-regulation of genes encoding the voltage-gated potassium channel (Kv1.5), ␤1-adrenergic receptor (ADRB1), and sarcoplasmic reticulum calcium ATPase (SERCA), and reduced expression of phospholamban (PLB) (the negative regulator of SERCA) (18, 19) . Such changes might lead to improved cardiovascular status, increasing the quality and yield of donor hearts. Whether such changes can occur in human cardiac donors within the timescale between consent and retrieval for transplantation is unknown. We therefore measured the relative mRNA expression of Kv1.5, ADRB1, SERCA 2a isoform (SERCA2a), and PLB in left ventricular (LV) free wall biopsies after T 3 administration in potential cardiac donors.
Subjects and Methods

Study design
This is a substudy of a previously reported randomized controlled trial of T 3 and methylprednisolone therapy in potential heart donors (17) . Within the trial, the next-of-kin of 30 donors receiving either placebo (n ϭ 14) or isolated T 3 (n ϭ 16) consented to LV biopsy, and these constitute the study population.
The research was approved by a multicenter research ethics committee, and consent was obtained from donor next-of-kin.
Thyroid function
Blood samples for thyroid function tests were drawn at baseline and repeated after 4 h of donor management. Serum was decanted and stored at Ϫ80 C for batch analysis of free T 4 (fT4), fT3, and TSH using a chemiluminescent assay system (Advia Centaur analyzer; Siemens Healthcare Diagnostics Limited, Newark, DE). Reference ranges were: fT4, 11.0 -26.0 pmol ⅐ liter Ϫ1 ; fT3, 3.3-7.5 pmol ⅐ liter Ϫ1 ; and TSH, 0.4 -6.3 mIU ⅐ liter Ϫ1 . A low T 3 state was predefined as fT3 level below the lower reference limit. 
Donor management
Randomization, hormonal therapy, and outcome
After initial sampling and assessment, the study donors received T 3 (0.8 g ⅐ kg Ϫ1 bolus), followed by an infusion of 0.113 g ⅐ kg Ϫ1 ⅐ h Ϫ1 (6) or placebo (5% dextrose) according to their randomization (17) .
LV biopsies
Within the operating room, at end-assessment and before aortic clamping, full-thickness free wall LV biopsies were obtained using tru-cut bioptomes (Allegiance, McGaw Park, IL), snap-frozen in liquid nitrogen, and then stored at Ϫ80 C. Total RNA was extracted using the Sigma Trisol kit (Sigma, St. Louis, MO) and further purified using the QIAGEN RNeasy miniprep (QIAGEN, Germantown, MD) clean-up procedure. Quantitative RT-PCR studies for the expression of specific mRNAs were performed using established methods (20) . All reactions were multiplexed with a preoptimized control probe for 18s rRNA (Applied Biosystems Inc., Warrington, UK). Primer and probe sequences for ADRB1, SERCA2a, and PLB have been published previously (21) . Probes for Kv1.5 were obtained from the manufacturer (Applied Biosystems). Target gene probes were labeled with 6-carboxy-flourescein, and housekeeping gene with VIC (full chemical name patent protected; Applied Biosystems Inc., Warrington, UK). Reactions were 50 C for 2 min, 95 C for 10 min, then 40 cycles of 95 C for 15 sec and 60 C for 1 min. All RT-PCR assays were repeated at least thrice.
Statistical analysis
Data were analyzed using SPSS version 15.0 (SPSS, Inc., Chicago, IL). Categorical data were compared using 2 testing. Continuous data were assessed for normality and are presented as mean [95% confidence interval] or median (interquartile range). Normally distributed data were compared using a one-way ANOVA, and skewed data were analyzed nonparametrically (Mann-Whitney U test). Differences between initial assessment and preretrieval values within groups were assessed by paired samples t tests and serial measurement group comparisons by repeated measures ANOVA. Expression data for mRNA are reported as cycle threshold (Ct) values and are used to determine ⌬Ct values [⌬Ct ϭ Ct of the target gene (e.g. ADRB1) minus Ct of the housekeeping gene (18s)]. Statistical comparisons were performed with ⌬Ct values (20) . Statistical significance was assigned when the P value was Ͻ 0.05.
Results
Demographic and clinical characteristics were similar in the 30 biopsied donors (Table 1) .
Thyroid function studies
Initial concentrations of fT3, fT4, and TSH were not different between groups. Low fT3 levels were present initially in nine of 14 (64%) placebo donors and in 10 of 12 (83%) at second measurement. In T 3 donors, eight of 15 (53%) had initial low serum fT3 levels. T 3 treatment increased fT3 to normal or supraphysiological levels in all T 3 donors (P Ͻ 0.001).
Hemodynamic data
Baseline hemodynamic parameters were not different between groups (Table 1) . CVP, PCWP, and CI increased between initial assessment and preretrieval in both groups and SVRI fell, but there was no difference between groups (repeated measures ANOVA; CI, P ϭ 0.987; SVRI, P ϭ 0.556; interval data not shown). LVSWI and CPOi did not change. The number of donors on norepinephrine, vasopressin, and inotropes at baseline and preretrieval were not different.
mRNA changes
Expression of Kv1.5 mRNA was increased 1.99-fold in T 3 hearts vs. placebo (P ϭ 0.015) (Fig. 1) . Increased expression of ADRB1 and PLB mRNA was not observed (0.84-fold and 1.24-fold, T 3 vs. placebo, P ϭ 0.475 and 0.273, respectively). A 1.51-fold increase in the expression of the mRNA encoding for SERCA2a was noted after T 3 (P ϭ 0.043) (Fig. 1, A-D) .
Discussion
The role of TH supplementation to optimize the BSD cardiac donor remains controversial. Despite a lack of randomized clinical trial evidence, T 3 is commonly used in an attempt to improve myocardial function and donor organ usability. The present study demonstrates that T 3 therapy after BSD increases fT3 and the expression of mRNAs encoding Kv1.5 and SERCA2a, but not those encoding ADRB1 or PLB. Although T 3 may act nongenomically to elicit vasodilatation, we did not demonstrate a T 3 effect on cardiovascular performance, a change in vascular resistance, or requirement for vasoconstrictor therapy.
In chronic hyperthyroidism, improved inotropy and lusitropy have been observed. These effects are believed to be secondary to alterations in the ratio of expression of SERCA and PLB (22, 23) and increased expression of ADRB1 (24) . However, the duration of TH elevation or treatment period required to induce such effects in humans is unknown. Cardiac up-regulation of Kv1.5 and SERCA2a may occur rapidly (within 1-2 h) in hypothyroid animals after exogenous T 3 administration (18, 25) . Our study confirms that these rapid effects also occur in humans. PLB mRNA expression is negatively regulated by T 3 . In animal models, T 3 lowers PLB levels and increases its phosphorylation state, enhancing SERCA activity (22, 23, 26, 27) . The failure of T 3 to down-regulate PLB in this study may reflect the limited duration of therapy and may be responsible for the absence or attenuation of a hemodynamic effect.
In cultured cardiomyocytes, T 3 increases the expression of ADRB1 mRNA-maximal at 2 h and sustained for 72 h (28) . If these changes occurred acutely in the donor, they could potentially enhance donor heart performance. However, despite increasing receptor expression, acute T 3 may not increase catecholamine sensitivity (24) . We were unable to demonstrate any effect of T 3 on ADRB1 mRNA expression, and we conclude that this is an unlikely mechanism by which T 3 could exert a salutary cardiac effect in the heart donor, within the timeframe of administration in this study.
The controversy regarding T 3 treatment of the potential heart donor is fueled by several conflicting experimental and clinical observations. Administration of TH after BSD in animal models can improve hemodynamic function before and after transplantation (29 -31) . In addition, initial reports of T 3 supplementation in dysfunctional human donor hearts suggested improved function with reduced vasopressor requirements (32) , and observational registry data have suggested that hormone replacement incorporating T 4 (or T 3 ) may increase transplant heart yield and reduce early failure rate (15, 33) . However, in these registry reports TH therapy alone was not beneficial, and the early clinical data were not corroborated by later work (34) . Moreover, randomized studies failed to demonstrate any benefit of supplemental T 3 therapy (16, 17) . Thus, the role of T 3 in donor management remains a subject of debate. In this study, T 3 was administered for a longer duration at an adequate dosage leading to supra-normal fT3 levels in all T 3 recipients. The partial genomic response that we observed may infer that a longer duration of treatment, which may be impractical in organ donation, could induce further positive genomic and hemodynamic changes in donor or recipients.
In summary, in this limited study, although the administration of T 3 in the BSD cardiac donor increases fT3 and the expression of mRNA for Kv1.5 and SERCA2a, these changes are not accompanied by changes in ADRB1 or PLB and were not associated with an improvement in hemodynamic performance in the context of this study.
Study limitations
In this clinical study, we were not able to initiate donor management or hormonal therapy until at least 12 h after BSD. Although the dosing and timing of T 3 administration could be changed, it is unlikely within the current processes involved in identification and consent of the BSD donor that treatment could be initiated consistently at an earlier timepoint. Although all recipients survived, we do not have detailed data regarding early posttransplant function, and it is possible that donor T 3 therapy could confer benefits to the recipient. We did not specifically investigate changes in protein expression due to the relatively short time of T 3 administration.
